Eledoisin - CAS 69-25-0
Catalog number: 69-25-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C54H85N13O15S
Molecular Weight:
1188.41
COA:
Inquire
Targets:
Others
Description:
Eledoisin is an undecapeptide of mollusk origin and it belongs to the tachykinin family of neuropeptides. It was first isolated from the posterior salivary glands of two mollusk species Eledone muschata and Eledone aldovandi. Eledoisin has the amino acid sequence pGlu-Pro-Ser-Lys-Asp-Ala-Phe-Ile-Gly-Leu-Met-NH2. It is the Potent natural tachykinin receptor ligand.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Appearance:
White lyophilised solid
Synonyms:
eledonepeptide;ELEDOISIN;GLP-PRO-SER-LYS-ASP-ALA-PHE-ILE-GLY-LEU-MET-NH2;5-oxo-l-prolyl-l-prolyl-l-seryl-l-lysyl-l-aspartyl-l-alanyl-l-phenylalanyl-l-isoleucylglycyl-l-leucyl-l-methioninamide;PYR-PRO-SER-LYS-ASP-ALA-PHE-ILE-GLY-LEU-MET-NH2;PYR-PSKDAFIGLM;(3S)-3-[[(2S)-6-amino-2-[[(2S)-3-hydroxy-2-[[(2S)-1-[(2S)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
Solubility:
Soluble to 0.20 mg/ml in water
Storage:
-20℃ Freezer
MSDS:
Inquire
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
Density:
1.289 g/cm3
InChIKey:
AYLPVIWBPZMVSH-FCKMLYJASA-N
InChI:
InChI=1S/C54H85N13O15S/c1-7-30(4)44(53(81)57-27-42(70)60-36(24-29(2)3)49(77)61-33(45(56)73)20-23-83-6)66-50(78)37(25-32-14-9-8-10-15-32)63-46(74)31(5)58-48(76)38(26-43(71)72)64-47(75)34(16-11-12-21-55)62-51(79)39(28-68)65-52(80)40-17-13-22-67(40)54(82)35-18-19-41(69)59-35/h8-10,14-15,29-31,33-40,44,68H,7,11-13,16-28,55H2,1-6H3,(H2,56,73)(H,57,81)(H,58,76)(H,59,69)(H,60,70)(H,61,77)(H,62,79)(H,63,74)(H,64,75)(H,65,80)(H,66,78)(H,71,72)/t30-,31-,33-,34-,35-,36-,37-,38-,39-,40-,44-/m0/s1
Canonical SMILES:
CCC(C)C(C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C2CCCN2C(=O)C3CCC(=O)N3
1.Structural heterogeneity of doubly-charged peptide b-ions.
Li X1, Huang Y, O'Connor PB, Lin C. J Am Soc Mass Spectrom. 2011 Feb;22(2):245-54. doi: 10.1007/s13361-010-0036-1. Epub 2011 Jan 29.
Performing collisionally activated dissociation (CAD) and electron capture dissociation (ECD) in tandem has shown great promise in providing comprehensive sequence information that was otherwise unobtainable by using either fragmentation method alone or in duet. However, the general applicability of this MS(3) approach in peptide sequencing may be undermined by the formation of non-direct sequence ions, as sometimes observed under CAD, particularly when multiple stages of CAD are involved. In this study, varied-sized doubly-charged b-ions from three tachykinin peptides were investigated by ECD. Sequence scrambling was observed in ECD of all b-ions from neurokinin A (HKTDSFVGLM-NH(2)), suggesting the presence of N- and C-termini linked macro-cyclic conformers. On the contrary, none of the b-ions from eledoisin (pEPSKDAFIGLM-NH(2)) produced non-direct sequence ions under ECD, as it does not contain a free N-terminal amino group. ECD of several b-ions from Substance P (RPKPQQFFGLM-NH(2)) showed series of c(m)-Lys fragment ions which suggested that the macro-cyclic structure may also be formed by connecting the C-terminal carbonyl group and the ε-amino group of the lysine side chain.
2.Characterization of receptors for two Xenopus gastrointestinal tachykinin peptides in their species of origin.
Johansson A1, Liu L, Holmgren S, Burcher E. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):35-45. Epub 2004 Jul 2.
Two tachykinin peptides, bufokinin and Xenopus neurokinin A (X-NKA) were recently isolated from Xenopus laevis. In this study we investigated the tachykinin receptors in the Xenopus gastrointestinal tract. In functional studies using stomach circular muscle strips, all peptides had similar potencies (EC50 values 1-7 nM). The rank order of potency to contract the intestine was physalaemin (EC50 1 nM)> or =bufokinin (EC50 3 nM)>substance P (SP)> or =cod SP>NKA>>X-NKA (EC50 1,900 nM). No maximum response could be obtained for [Sar9,Met(O2)11]SP, eledoisin and kassinin. In stomach strips, the mammalian tachykinin receptor antagonists RP 67580 (NK1) and MEN 10376 (NK2) had agonistic effects but did not antagonize bufokinin or X-NKA. In intestinal strips, RP 67580 (1 microM) reduced the maximal response to X-NKA but not bufokinin, while MEN 10376 was ineffective. [125I]BH-bufokinin bound with high affinity to a single class of sites, of KD 213+/-35 (stomach) and 172+/-9.
3.Eledoisin and Kassinin, but not Enterokassinin, stimulate ion transport in frog skin.
Lippe C1, Bellantuono V, Ardizzone C, Cassano G. Peptides. 2004 Nov;25(11):1971-5.
In frog skin, tachykinins stimulate the ion transport, estimated by measuring the short-circuit current (SCC) value, by interacting with NK1-like receptors. In this paper we show that Kassinin (NK2 preferring in mammals) increases the SCC, while Enterokassinin has no effect. Therefore, either 2 Pro residues or 1 Pro and 1 basic amino acid must be present in the part exceeding the C-terminal pentapeptide. Eledoisin (NK3 preferring in mammals) stimulation of SCC is reduced by CP99994 and SR48968 (NK1 and NK2 antagonists) and not affected by SB222200 (NK3 antagonist). None of the three antagonists affects Kassinin stimulation of SCC.
4.Iatrogenic dry eye disease: an eledoisin/carnitine and osmolyte drops study.
Nebbioso M1, Evangelista M, Librando A, Plateroti AM, Pescosolido N. Biomed Pharmacother. 2013 Sep;67(7):659-63. doi: 10.1016/j.biopha.2013.07.001. Epub 2013 Jul 12.
BACKGROUND: To evaluate the effects of an eye drop containing eledoisin and carnitine in patients suffering from primary open-angle glaucoma (POAG) and ocular discomfort syndrome secondary to a chronically treated with eye drops containing benzalkonium chloride (BAK) as preservative. The dry eye disease was defined as a multifactorial drop disease concerning tears and ocular surface, which brings to discomfort symptoms and visual disorders with potential damage to the ocular surface. Several studies underlined the beneficial effects of secretagogues drugs, such as eledoisin. It is a neuro-peptide extracted from the salivary glands of some shellfishes. Recently, it has been also showed the protective role of carnitine in respect of the ocular surface exposed to the tear film hyperosmolarity.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 590368-25-5 Upamostat

Upamostat
(CAS: 590368-25-5)

Upamostat is the prodrug of serine protease inhibitor WX-UK1 targeting the human urokinase plasminogen activator (uPA) system. Upamostat exhibits potential anti...

CAS 507471-72-9 Caffeic acid-pYEEIE

Caffeic acid-pYEEIE
(CAS: 507471-72-9)

Caffeic acid-pYEEIE has been found to be a phosphopeptide ligand.

CAS 58821-95-7 Tinyatoxin

Tinyatoxin
(CAS: 58821-95-7)

Tinyatoxin is a neurotoxin, acting via vanilloid receptors of sensory nerves.

CAS 84272-85-5 4-O-beta-D-gulcosyl-5-O-methylvisamminol

4-O-beta-D-gulcosyl-5-O-methylvisamminol
(CAS: 84272-85-5)

4-O-β-D-Glucosyl-5-O-methyllvisamminol is a natural product isolated from the roots of Saposhnikovia divaricata (Turcz.) Schischk. It is a novel epigenetic supp...

CAS 3317-67-7 Phthalocyanine Cobalt(II)

Phthalocyanine Cobalt(II)
(CAS: 3317-67-7)

Cobalt phthalocyanine, a novel molecular recognition reagent, is a catalyst of redox reaction

CP-472555
(CAS: 305821-96-9)

CP-472555 is an effective Glucocorticoid receptor agonist and probably has steroid-like anti-inflammatory properties with anti-GR and anti-obesity activity in a...

CAS 24587-49-3 trans-4-Hydroxycrotonic acid

trans-4-Hydroxycrotonic acid
(CAS: 24587-49-3)

trans-4-Hydroxycrotonic acid has high affinity for the γ-hydroxybutyric acid (GHB) receptor. It may be an endogenous ligand.

SPDB
(CAS: 115088-06-7)

SPDB, a pyridyldithioyl compound, has been found to link to DM4 conjugates and probably influence the releasement of cytotoxic metabolitesin.

BI-44847
(CAS: 421592-30-5)

BI-44847 is a synthetic bio-active chemical had been in phase II clinical trials for the treatment of type 2 diabetes.

MitoE10
(CAS: 1810703-63-9)

MitoE10, a mitochondria-targeted antioxidants comprising a lipophilic triphenylphosphonium cation attached to the antioxidant chroman moiety of vitamin E by an ...

Clamoxyquin Hydrochloride
(CAS: 4724-59-8)

Clamoxyquine, as the pamoate or hydrochloride salt, is an antiamebic and antidiarrheal drug used as a veterinary medicine to treat salmonids for infection with ...

CAS 21463-31-0 AMT hydrochloride

AMT hydrochloride
(CAS: 21463-31-0)

The hydrochloride salt form of AMT, which has been found to be a reversible inhibitor of iNOS and could probably be useful in treatment of inflammatory and auto...

CAS 856676-23-8 Choline Fenofibrate

Choline Fenofibrate
(CAS: 856676-23-8)

Choline Fenofibrate is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipide...

CGP 43182
(CAS: 150379-37-6)

CGP 43182, a dioxaspiro compound, has been found to a IIA sPLA2 inhibitor that could have potential anti-inflammatory effect and also in influencing the synergi...

CAS 80681-45-4 Prim-o-glucosylcimifugin

Prim-o-glucosylcimifugin
(CAS: 80681-45-4)

Prim-O-glucosylcimifugin is a natural product extracted from the root of Saposhnikovia divaricata (Turcz.) Schischk. It can inhibit the proliferation of SMC(smo...

CAS 343306-79-6 Sugammadex

Sugammadex
(CAS: 343306-79-6)

Sugammadex, a modified γ-cyclodextrin, with a lipophilic core and a hydrophilic periphery, is an agent for reversal of neuromuscular blockade by the agent rocu...

DPY-6602
(CAS: 145696-60-2)

DPY-6602, a pyrrole derivative, could be widely used as an intermediate in sorts of areas like photosensitizers and antitumor drugs.

CK-2289
(CAS: 101183-99-7)

CK-2289 is an type III cyclic 3'5'-adenosine monophosphate phosphodiesterase inhibitor. It may be used in the treatment of congestive heart failure.

LY 164929
(CAS: 113573-18-5)

This active molecular is a highly selective ligand for the lower affinity [3H]D-Ala2-D-Leu-5-enkephalin binding site.

CAS 15291-77-7 Ginkgolide B

Ginkgolide B
(CAS: 15291-77-7)

Ginkgolide B is a PAFR antagonist with IC50 of 3.6 μM.

Chemical Structure

CAS 69-25-0 Eledoisin

Quick Inquiry

Verification code

Featured Items